Trial Profile
Efficacy of lenalidomide in the treatment of patients with non-Hodgkin's lymphoma (SPA)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 22 Jan 2009
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms SPA
- Sponsors Celgene Corporation
- 22 Jan 2009 New trial record.
- 13 Jan 2009 Celegene expects to start this trial in 2009.